Dickison Philippa, Swain Grace, Peek Jonathan J, Smith Saxon D
Department of Dermatology, Northern Clinical School, University of Sydney, Sydney, New South Wales, Australia.
Department of Dermatology, Royal North Shore Hospital, Sydney, New South Wales, Australia.
Australas J Dermatol. 2018 Aug;59(3):206-209. doi: 10.1111/ajd.12747. Epub 2017 Dec 26.
BACKGROUND/OBJECTIVES: Pruritus is the most frequently reported complaint or symptom for psoriasis patients. Despite the morbidity associated with pruritus in psoriasis few studies have evaluated the prevalence of itch in psoriasis with the current use of biological agents.
This was a multi-site cross-sectional observational study conducted in New South Wales, Australia. Psoriasis patients were approached during their outpatient clinic, phototherapy or private consultations. Data on psoriasis characteristics, severity and treatment were collected. The patients were then asked to complete a survey regarding the frequency, severity and aggravators of their psoriasis.
Data were collected from 179 patients with a mean age of 52.3 years, of whom 55% were male. Altogether 63 (35%) had a psoriasis area severity index (PASI) > 10, 42 (24%) were on biological agents and 84 (47%) were receiving phototherapy. The number of patients who reported itch all the time was 40 (22%), most of the time 48 (27%), and never 19 (11%). Patients with nail psoriasis were significantly less likely to have itch all or most of the time (P = 0.01). Itch all or most of the time was significantly more likely in patients with PASI > 10 (P = 0.013). No treatment was associated with reduced itch. Itch was reported to be most frequent in the winter season.
Few patients with psoriasis do not suffer from pruritus. Despite their promise, biological agents are not associated with reduced itch.
背景/目的：瘙痒是银屑病患者最常报告的主诉或症状。尽管银屑病瘙痒会带来不良影响，但目前很少有研究评估使用生物制剂治疗的银屑病患者中瘙痒的患病率。
这是一项在澳大利亚新南威尔士州进行的多中心横断面观察性研究。在银屑病患者门诊、光疗或私人咨询期间对其进行随访。收集银屑病特征、严重程度和治疗的数据。然后要求患者完成一项关于银屑病瘙痒频率、严重程度和加重因素的调查。
共收集了179例患者的数据，平均年龄52.3岁，其中55%为男性。共有63例（35%）银屑病面积和严重程度指数（PASI）>10，42例（24%）正在使用生物制剂，84例（47%）正在接受光疗。报告一直瘙痒的患者有40例（22%），大部分时间瘙痒的有48例（27%），从不瘙痒的有19例（11%）。甲银屑病患者在全部或大部分时间出现瘙痒的可能性显著降低（P = 0.01）。PASI>10的患者在全部或大部分时间出现瘙痒的可能性显著更高（P = 0.013）。没有哪种治疗方法与瘙痒减轻相关。据报告冬季瘙痒最为频繁。
很少有银屑病患者不伴有瘙痒。尽管生物制剂前景良好，但它们与瘙痒减轻无关。
